NCT06500793View on ClinicalTrials.gov

Single and Multi-Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 24, 2024

Primary Completion Date

January 30, 2026

Study Completion Date

March 27, 2026

Conditions
Pharmacokinetics
Interventions
DRUG

PF614 capsule

PF614 capsules (25-100 mg)

DRUG

Nafamostat Mesylate

Nafamostat IR/ER solution/beads (total 1-10 mg)

Trial Locations (1)

33126

RECRUITING

Quotient Sciences, Miami

Sponsors
All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

Ensysce Biosciences

INDUSTRY